Clinical Trial Update: A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase II study evaluating SC10914 for metastatic breast cancer with BRCA mutations; results not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SC10914

Snippet

Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation | Phase 2 | Status: UNKNOWN